Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study

L. Taramasso
A. Di Biagio
N. Riccardi
F. Briano
E. Di Filippo
L. Comi
S. Mora
M. Giacomini
A. Gori
F. Maggiolo

Open PDF

Open link

Publication date

January 2019

Publisher

Grupo Comunicar

Language

English

Abstract

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this study was to evaluate the impact on lipids of switching from rilpivirine (RPV)/ emtricitabine (FTC)/TDF to RPV/FTC/TAF in a large cohort of HIV-1 infected patients

Extracted data

We use cookies to provide a better user experience.

Data Protection

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study

L. Taramasso
A. Di Biagio
N. Riccardi
F. Briano
E. Di Filippo
L. Comi
S. Mora
M. Giacomini
A. Gori
F. Maggiolo

Open PDF

Open link

Publication date

January 2019

Publisher

Grupo Comunicar

Language

English

Abstract

Extracted data

Andrea Giacomelli
Federico Conti
Laura Pezzati
Letizia Oreni
Anna Lisa Ridolfo
Valentina Morena
Cecilia Bonazzetti
Gabriele Pagani
Tiziana Formenti
Massimo Galli
Stefano Rusconi

June 2021

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch...

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

Taramasso L.
Tatarelli P.
Ricci E.
Madeddu G.
Menzaghi B.
Squillace N.
De Socio G. V.
Martinelli C.
Gulminetti R.
Maggi P.
Orofino G.
Vichi F.
Di Biagio A.
Bonfanti P.
Bellacosa C.
Calza L.
Abeli C.
Celesia B. M.
Grosso C.
Stagno A.
Mazzotta F.
Penco G.
Cassola G.
Nicolini L. A.
Dentone C.
Molteni C.
Palvarini L.
Scalzini A.
Carenzi L.
Rizzardini G.
Valsecchi L.
Cordier L.
Rusconi S.
Colombo V.
Galli M.
Franzetti M.
Sgrelli A.
Mazzotta E.
Parruti G.
Bagella P.
Mura M. S.
Libertone R.
Antinori A.
Di Giambenedetto S.
Guastavigna M.
Caramello P.

January 2018

Background: Dyslipidemia represents a significant non-infectious comorbidity among people living wit...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.

Pérez-Hernández, Isabel A
Palacios, Rosario
Mayorga, Marisa
González-Doménech, Carmen M
Castaño, Manuel
Rivero, Antonio
Arco, Alfonso del
Lozano, Fernando
Santos, Jesús

November 2014

Meeting abstract. Abstracts of the HIV Drug Therapy Glasgow Congress 2014INTRODUCTION Rilpivirine (...

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations. Results from a large observational study

L. Taramasso
A. Di Biagio
N. Riccardi
F. Briano
E. Di Filippo
L. Comi
S. Mora
M. Giacomini
A. Gori
F. Maggiolo

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), b...

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.

Lucia Taramasso
Antonio Di Biagio
Niccolò Riccardi
Federica Briano
Elisa Di Filippo
Laura Comi
Sara Mora
Mauro Giacomini
Andrea Gori
Franco Maggiolo

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/ emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia

Taramasso L.
Di Biagio A.
Riccardi N.
Briano F.
Di Filippo E.
Comi L.
Mora S.
Giacomini M.
Gori A.
Maggiolo F.

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...

Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.

Ocampo, A
Domingo, P
Fernández, P
Diz, J
Barberá, J R
Sepúlveda, M A
Salgado, X
Rodriguez, M
Santos, J
Yzusqui, M
Mayorga, M I
Lorenzo, J F
Bahamonde, A
Bachiller, P
Martínez, E
Rozas, N
Torres, C
Muñoz, A
Casado, A
Podzamczer, D

January 2018

To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their an...

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.

Surial, B.
Mugglin, C.
Calmy, A.
Cavassini, M.
Günthard, H.F.
Stöckle, M.
Bernasconi, E.
Schmid, P.
Tarr, P.E.
Furrer, H.
Ledergerber, B.
Wandeler, G.
Rauch, A.

June 2021

Tenofovir-based antiretroviral therapy (ART) has become first-line in all major HIV treatment guidel...

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study

Surial, Bernard
Mugglin, Catrina
Calmy, Alexandra
Cavassini, Matthias
Günthard, Huldrych F
Stöckle, Marcel
Bernasconi, Enos
Schmid, Patrick
Tarr, Philip E
Furrer, Hansjakob
Ledergerber, Bruno
Wandeler, Gilles
Rauch, Andri
Swiss HIV Cohort Study

June 2021

BACKGROUND Tenofovir-based antiretroviral therapy (ART) has become first-line in all major HIV tr...

Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients

Lagoutte-Renosi, Jennifer
Flammang, Mylène
Chirouze, Catherine
Beckwirth, Geneviève
Bozon, Fabienne
Brunel, Anne-Sophie
Drobacheff-Thiebaut, Marie-Christine
Foltzer, Adeline
Hustache-Mathieu, Laurent
Kowalczyk, Jakub
Michel, Catherine
Davani, Siamak
Muret, Patrice

August 2020

International audienceTenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that expos...

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.

Plum, Pierre-Emmanuel
Maes, Nathalie
Sauvage, Anne-Sophie
Frippiat, Frédéric
Meuris, Christelle
Uurlings, Françoise
Lecomte, Marianne
Léonard, Philippe
Paquot, Nicolas
Fombellida, Karine
Vaira, Dolores
Moutschen, Michel
Darcis, Gilles

January 2021

peer reviewedBACKGROUND: As cardiovascular diseases represent the main cause of non-AIDS related dea...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114

Isabel A Pérez-Hernández
Rosario Palacios
Marisa Mayorga
Carmen M González-Doménech
Manuel Castaño
Antonio Rivero
Alfonso del Arco
Fernando Lozano
Jesús Santos

November 2014

Introduction: Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients (1...

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

Andrea Giacomelli
Federico Conti
Laura Pezzati
Letizia Oreni
Anna Lisa Ridolfo
Valentina Morena
Cecilia Bonazzetti
Gabriele Pagani
Tiziana Formenti
Massimo Galli
Stefano Rusconi

June 2021

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch...

Taramasso L.
Tatarelli P.
Ricci E.
Madeddu G.
Menzaghi B.
Squillace N.
De Socio G. V.
Martinelli C.
Gulminetti R.
Maggi P.
Orofino G.
Vichi F.
Di Biagio A.
Bonfanti P.
Bellacosa C.
Calza L.
Abeli C.
Celesia B. M.
Grosso C.
Stagno A.
Mazzotta F.
Penco G.
Cassola G.
Nicolini L. A.
Dentone C.
Molteni C.
Palvarini L.
Scalzini A.
Carenzi L.
Rizzardini G.
Valsecchi L.
Cordier L.
Rusconi S.
Colombo V.
Galli M.
Franzetti M.
Sgrelli A.
Mazzotta E.
Parruti G.
Bagella P.
Mura M. S.
Libertone R.
Antinori A.
Di Giambenedetto S.
Guastavigna M.
Caramello P.

January 2018

Background: Dyslipidemia represents a significant non-infectious comorbidity among people living wit...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.

Pérez-Hernández, Isabel A
Palacios, Rosario
Mayorga, Marisa
González-Doménech, Carmen M
Castaño, Manuel
Rivero, Antonio
Arco, Alfonso del
Lozano, Fernando
Santos, Jesús

November 2014

Meeting abstract. Abstracts of the HIV Drug Therapy Glasgow Congress 2014INTRODUCTION Rilpivirine (...

L. Taramasso
A. Di Biagio
N. Riccardi
F. Briano
E. Di Filippo
L. Comi
S. Mora
M. Giacomini
A. Gori
F. Maggiolo

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), b...

Lucia Taramasso
Antonio Di Biagio
Niccolò Riccardi
Federica Briano
Elisa Di Filippo
Laura Comi
Sara Mora
Mauro Giacomini
Andrea Gori
Franco Maggiolo

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/ emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia

Taramasso L.
Di Biagio A.
Riccardi N.
Briano F.
Di Filippo E.
Comi L.
Mora S.
Giacomini M.
Gori A.
Maggiolo F.

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...

Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.

Ocampo, A
Domingo, P
Fernández, P
Diz, J
Barberá, J R
Sepúlveda, M A
Salgado, X
Rodriguez, M
Santos, J
Yzusqui, M
Mayorga, M I
Lorenzo, J F
Bahamonde, A
Bachiller, P
Martínez, E
Rozas, N
Torres, C
Muñoz, A
Casado, A
Podzamczer, D

January 2018

To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their an...

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.

Surial, B.
Mugglin, C.
Calmy, A.
Cavassini, M.
Günthard, H.F.
Stöckle, M.
Bernasconi, E.
Schmid, P.
Tarr, P.E.
Furrer, H.
Ledergerber, B.
Wandeler, G.
Rauch, A.

June 2021

Tenofovir-based antiretroviral therapy (ART) has become first-line in all major HIV treatment guidel...

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study

Surial, Bernard
Mugglin, Catrina
Calmy, Alexandra
Cavassini, Matthias
Günthard, Huldrych F
Stöckle, Marcel
Bernasconi, Enos
Schmid, Patrick
Tarr, Philip E
Furrer, Hansjakob
Ledergerber, Bruno
Wandeler, Gilles
Rauch, Andri
Swiss HIV Cohort Study

June 2021

BACKGROUND Tenofovir-based antiretroviral therapy (ART) has become first-line in all major HIV tr...

Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients

Lagoutte-Renosi, Jennifer
Flammang, Mylène
Chirouze, Catherine
Beckwirth, Geneviève
Bozon, Fabienne
Brunel, Anne-Sophie
Drobacheff-Thiebaut, Marie-Christine
Foltzer, Adeline
Hustache-Mathieu, Laurent
Kowalczyk, Jakub
Michel, Catherine
Davani, Siamak
Muret, Patrice

August 2020

International audienceTenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that expos...

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.

Plum, Pierre-Emmanuel
Maes, Nathalie
Sauvage, Anne-Sophie
Frippiat, Frédéric
Meuris, Christelle
Uurlings, Françoise
Lecomte, Marianne
Léonard, Philippe
Paquot, Nicolas
Fombellida, Karine
Vaira, Dolores
Moutschen, Michel
Darcis, Gilles

January 2021

peer reviewedBACKGROUND: As cardiovascular diseases represent the main cause of non-AIDS related dea...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114

Isabel A Pérez-Hernández
Rosario Palacios
Marisa Mayorga
Carmen M González-Doménech
Manuel Castaño
Antonio Rivero
Alfonso del Arco
Fernando Lozano
Jesús Santos

November 2014

Introduction: Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients (1...

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

Andrea Giacomelli
Federico Conti
Laura Pezzati
Letizia Oreni
Anna Lisa Ridolfo
Valentina Morena
Cecilia Bonazzetti
Gabriele Pagani
Tiziana Formenti
Massimo Galli
Stefano Rusconi

June 2021

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch...

Taramasso L.
Tatarelli P.
Ricci E.
Madeddu G.
Menzaghi B.
Squillace N.
De Socio G. V.
Martinelli C.
Gulminetti R.
Maggi P.
Orofino G.
Vichi F.
Di Biagio A.
Bonfanti P.
Bellacosa C.
Calza L.
Abeli C.
Celesia B. M.
Grosso C.
Stagno A.
Mazzotta F.
Penco G.
Cassola G.
Nicolini L. A.
Dentone C.
Molteni C.
Palvarini L.
Scalzini A.
Carenzi L.
Rizzardini G.
Valsecchi L.
Cordier L.
Rusconi S.
Colombo V.
Galli M.
Franzetti M.
Sgrelli A.
Mazzotta E.
Parruti G.
Bagella P.
Mura M. S.
Libertone R.
Antinori A.
Di Giambenedetto S.
Guastavigna M.
Caramello P.

January 2018

Background: Dyslipidemia represents a significant non-infectious comorbidity among people living wit...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.

Pérez-Hernández, Isabel A
Palacios, Rosario
Mayorga, Marisa
González-Doménech, Carmen M
Castaño, Manuel
Rivero, Antonio
Arco, Alfonso del
Lozano, Fernando
Santos, Jesús

November 2014

Meeting abstract. Abstracts of the HIV Drug Therapy Glasgow Congress 2014INTRODUCTION Rilpivirine (...

Andrea Giacomelli
Federico Conti
Laura Pezzati
Letizia Oreni
Anna Lisa Ridolfo
Valentina Morena
Cecilia Bonazzetti
Gabriele Pagani
Tiziana Formenti
Massimo Galli
Stefano Rusconi

June 2021

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch...

Taramasso L.
Tatarelli P.
Ricci E.
Madeddu G.
Menzaghi B.
Squillace N.
De Socio G. V.
Martinelli C.
Gulminetti R.
Maggi P.
Orofino G.
Vichi F.
Di Biagio A.
Bonfanti P.
Bellacosa C.
Calza L.
Abeli C.
Celesia B. M.
Grosso C.
Stagno A.
Mazzotta F.
Penco G.
Cassola G.
Nicolini L. A.
Dentone C.
Molteni C.
Palvarini L.
Scalzini A.
Carenzi L.
Rizzardini G.
Valsecchi L.
Cordier L.
Rusconi S.
Colombo V.
Galli M.
Franzetti M.
Sgrelli A.
Mazzotta E.
Parruti G.
Bagella P.
Mura M. S.
Libertone R.
Antinori A.
Di Giambenedetto S.
Guastavigna M.
Caramello P.

January 2018

Background: Dyslipidemia represents a significant non-infectious comorbidity among people living wit...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.

Pérez-Hernández, Isabel A
Palacios, Rosario
Mayorga, Marisa
González-Doménech, Carmen M
Castaño, Manuel
Rivero, Antonio
Arco, Alfonso del
Lozano, Fernando
Santos, Jesús

November 2014

Meeting abstract. Abstracts of the HIV Drug Therapy Glasgow Congress 2014INTRODUCTION Rilpivirine (...

L. Taramasso
A. Di Biagio
N. Riccardi
F. Briano
E. Di Filippo
L. Comi
S. Mora
M. Giacomini
A. Gori
F. Maggiolo

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), b...

Lucia Taramasso
Antonio Di Biagio
Niccolò Riccardi
Federica Briano
Elisa Di Filippo
Laura Comi
Sara Mora
Mauro Giacomini
Andrea Gori
Franco Maggiolo

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/ emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia

Taramasso L.
Di Biagio A.
Riccardi N.
Briano F.
Di Filippo E.
Comi L.
Mora S.
Giacomini M.
Gori A.
Maggiolo F.

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...

Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.

Ocampo, A
Domingo, P
Fernández, P
Diz, J
Barberá, J R
Sepúlveda, M A
Salgado, X
Rodriguez, M
Santos, J
Yzusqui, M
Mayorga, M I
Lorenzo, J F
Bahamonde, A
Bachiller, P
Martínez, E
Rozas, N
Torres, C
Muñoz, A
Casado, A
Podzamczer, D

January 2018

To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their an...

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.

Surial, B.
Mugglin, C.
Calmy, A.
Cavassini, M.
Günthard, H.F.
Stöckle, M.
Bernasconi, E.
Schmid, P.
Tarr, P.E.
Furrer, H.
Ledergerber, B.
Wandeler, G.
Rauch, A.

June 2021

Tenofovir-based antiretroviral therapy (ART) has become first-line in all major HIV treatment guidel...

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study

Surial, Bernard
Mugglin, Catrina
Calmy, Alexandra
Cavassini, Matthias
Günthard, Huldrych F
Stöckle, Marcel
Bernasconi, Enos
Schmid, Patrick
Tarr, Philip E
Furrer, Hansjakob
Ledergerber, Bruno
Wandeler, Gilles
Rauch, Andri
Swiss HIV Cohort Study

June 2021

BACKGROUND Tenofovir-based antiretroviral therapy (ART) has become first-line in all major HIV tr...

Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients

Lagoutte-Renosi, Jennifer
Flammang, Mylène
Chirouze, Catherine
Beckwirth, Geneviève
Bozon, Fabienne
Brunel, Anne-Sophie
Drobacheff-Thiebaut, Marie-Christine
Foltzer, Adeline
Hustache-Mathieu, Laurent
Kowalczyk, Jakub
Michel, Catherine
Davani, Siamak
Muret, Patrice

August 2020

International audienceTenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that expos...

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.

Plum, Pierre-Emmanuel
Maes, Nathalie
Sauvage, Anne-Sophie
Frippiat, Frédéric
Meuris, Christelle
Uurlings, Françoise
Lecomte, Marianne
Léonard, Philippe
Paquot, Nicolas
Fombellida, Karine
Vaira, Dolores
Moutschen, Michel
Darcis, Gilles

January 2021

peer reviewedBACKGROUND: As cardiovascular diseases represent the main cause of non-AIDS related dea...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114

Isabel A Pérez-Hernández
Rosario Palacios
Marisa Mayorga
Carmen M González-Doménech
Manuel Castaño
Antonio Rivero
Alfonso del Arco
Fernando Lozano
Jesús Santos

November 2014

Introduction: Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients (1...

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

Andrea Giacomelli
Federico Conti
Laura Pezzati
Letizia Oreni
Anna Lisa Ridolfo
Valentina Morena
Cecilia Bonazzetti
Gabriele Pagani
Tiziana Formenti
Massimo Galli
Stefano Rusconi

June 2021

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch...

Taramasso L.
Tatarelli P.
Ricci E.
Madeddu G.
Menzaghi B.
Squillace N.
De Socio G. V.
Martinelli C.
Gulminetti R.
Maggi P.
Orofino G.
Vichi F.
Di Biagio A.
Bonfanti P.
Bellacosa C.
Calza L.
Abeli C.
Celesia B. M.
Grosso C.
Stagno A.
Mazzotta F.
Penco G.
Cassola G.
Nicolini L. A.
Dentone C.
Molteni C.
Palvarini L.
Scalzini A.
Carenzi L.
Rizzardini G.
Valsecchi L.
Cordier L.
Rusconi S.
Colombo V.
Galli M.
Franzetti M.
Sgrelli A.
Mazzotta E.
Parruti G.
Bagella P.
Mura M. S.
Libertone R.
Antinori A.
Di Giambenedetto S.
Guastavigna M.
Caramello P.

January 2018

Background: Dyslipidemia represents a significant non-infectious comorbidity among people living wit...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.

Pérez-Hernández, Isabel A
Palacios, Rosario
Mayorga, Marisa
González-Doménech, Carmen M
Castaño, Manuel
Rivero, Antonio
Arco, Alfonso del
Lozano, Fernando
Santos, Jesús

November 2014

Meeting abstract. Abstracts of the HIV Drug Therapy Glasgow Congress 2014INTRODUCTION Rilpivirine (...

L. Taramasso
A. Di Biagio
N. Riccardi
F. Briano
E. Di Filippo
L. Comi
S. Mora
M. Giacomini
A. Gori
F. Maggiolo

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), b...

Lucia Taramasso
Antonio Di Biagio
Niccolò Riccardi
Federica Briano
Elisa Di Filippo
Laura Comi
Sara Mora
Mauro Giacomini
Andrea Gori
Franco Maggiolo

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/ emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia

Taramasso L.
Di Biagio A.
Riccardi N.
Briano F.
Di Filippo E.
Comi L.
Mora S.
Giacomini M.
Gori A.
Maggiolo F.

January 2019

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...

Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.

Ocampo, A
Domingo, P
Fernández, P
Diz, J
Barberá, J R
Sepúlveda, M A
Salgado, X
Rodriguez, M
Santos, J
Yzusqui, M
Mayorga, M I
Lorenzo, J F
Bahamonde, A
Bachiller, P
Martínez, E
Rozas, N
Torres, C
Muñoz, A
Casado, A
Podzamczer, D

January 2018

To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their an...

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.

Surial, B.
Mugglin, C.
Calmy, A.
Cavassini, M.
Günthard, H.F.
Stöckle, M.
Bernasconi, E.
Schmid, P.
Tarr, P.E.
Furrer, H.
Ledergerber, B.
Wandeler, G.
Rauch, A.

June 2021

Tenofovir-based antiretroviral therapy (ART) has become first-line in all major HIV treatment guidel...

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study

Surial, Bernard
Mugglin, Catrina
Calmy, Alexandra
Cavassini, Matthias
Günthard, Huldrych F
Stöckle, Marcel
Bernasconi, Enos
Schmid, Patrick
Tarr, Philip E
Furrer, Hansjakob
Ledergerber, Bruno
Wandeler, Gilles
Rauch, Andri
Swiss HIV Cohort Study

June 2021

BACKGROUND Tenofovir-based antiretroviral therapy (ART) has become first-line in all major HIV tr...

Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients

Lagoutte-Renosi, Jennifer
Flammang, Mylène
Chirouze, Catherine
Beckwirth, Geneviève
Bozon, Fabienne
Brunel, Anne-Sophie
Drobacheff-Thiebaut, Marie-Christine
Foltzer, Adeline
Hustache-Mathieu, Laurent
Kowalczyk, Jakub
Michel, Catherine
Davani, Siamak
Muret, Patrice

August 2020

International audienceTenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that expos...

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.

Plum, Pierre-Emmanuel
Maes, Nathalie
Sauvage, Anne-Sophie
Frippiat, Frédéric
Meuris, Christelle
Uurlings, Françoise
Lecomte, Marianne
Léonard, Philippe
Paquot, Nicolas
Fombellida, Karine
Vaira, Dolores
Moutschen, Michel
Darcis, Gilles

January 2021

peer reviewedBACKGROUND: As cardiovascular diseases represent the main cause of non-AIDS related dea...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114

Isabel A Pérez-Hernández
Rosario Palacios
Marisa Mayorga
Carmen M González-Doménech
Manuel Castaño
Antonio Rivero
Alfonso del Arco
Fernando Lozano
Jesús Santos

November 2014

Introduction: Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients (1...

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

Andrea Giacomelli
Federico Conti
Laura Pezzati
Letizia Oreni
Anna Lisa Ridolfo
Valentina Morena
Cecilia Bonazzetti
Gabriele Pagani
Tiziana Formenti
Massimo Galli
Stefano Rusconi

June 2021

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch...

Taramasso L.
Tatarelli P.
Ricci E.
Madeddu G.
Menzaghi B.
Squillace N.
De Socio G. V.
Martinelli C.
Gulminetti R.
Maggi P.
Orofino G.
Vichi F.
Di Biagio A.
Bonfanti P.
Bellacosa C.
Calza L.
Abeli C.
Celesia B. M.
Grosso C.
Stagno A.
Mazzotta F.
Penco G.
Cassola G.
Nicolini L. A.
Dentone C.
Molteni C.
Palvarini L.
Scalzini A.
Carenzi L.
Rizzardini G.
Valsecchi L.
Cordier L.
Rusconi S.
Colombo V.
Galli M.
Franzetti M.
Sgrelli A.
Mazzotta E.
Parruti G.
Bagella P.
Mura M. S.
Libertone R.
Antinori A.
Di Giambenedetto S.
Guastavigna M.
Caramello P.

January 2018

Background: Dyslipidemia represents a significant non-infectious comorbidity among people living wit...

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.

Pérez-Hernández, Isabel A
Palacios, Rosario
Mayorga, Marisa
González-Doménech, Carmen M
Castaño, Manuel
Rivero, Antonio
Arco, Alfonso del
Lozano, Fernando
Santos, Jesús

November 2014

Meeting abstract. Abstracts of the HIV Drug Therapy Glasgow Congress 2014INTRODUCTION Rilpivirine (...

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study

Abstract

Extracted data

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study

Abstract

Extracted data

Related items

Related items